Cite
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model.
MLA
Tanaka, Nobuyuki, et al. “Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line and Subsequent Second-Line Targeted Therapy: A Proposal of the Modified-IMDC Risk Model.” Urologic Oncology, vol. 35, no. 2, Feb. 2017, p. 39.e19-39.e28. EBSCOhost, https://doi.org/10.1016/j.urolonc.2016.10.001.
APA
Tanaka, N., Mizuno, R., Yasumizu, Y., Ito, K., Shirotake, S., Masunaga, A., Ito, Y., Miyazaki, Y., Hagiwara, M., Kanao, K., Mikami, S., Nakagawa, K., Momma, T., Masuda, T., Asano, T., Oyama, M., & Oya, M. (2017). Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model. Urologic Oncology, 35(2), 39.e19-39.e28. https://doi.org/10.1016/j.urolonc.2016.10.001
Chicago
Tanaka, Nobuyuki, Ryuichi Mizuno, Yota Yasumizu, Keiichi Ito, Suguru Shirotake, Ayako Masunaga, Yujiro Ito, et al. 2017. “Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line and Subsequent Second-Line Targeted Therapy: A Proposal of the Modified-IMDC Risk Model.” Urologic Oncology 35 (2): 39.e19-39.e28. doi:10.1016/j.urolonc.2016.10.001.